Clinical Validation of a Cell-free DNA assay for Early Lung Cancer Detection
Memorial Sloan Kettering Radiation Oncology shared on X:
“New in Cancer Discovery from The Pike Laboratory:
Changes in genome-wide cell-free DNA reflected genomic and chromatin characteristics of lung cancer. A machine learning model identify individuals who were more or less likely to have LCSM and could save lives.”
Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection published in Cancer Discovery
Autors: Peter J. Mazzone, Peter B. Bach, Jacob CareyCaitlin A. SchonewolfKatalin Bognar, Manmeet S. Ahluwalia, Marcia Cruz-CorreaDavid GieradaSonali Kotagiri, Kathryn Lloyd, Fabien Maldonado, Jesse D. Ortendahl, Lecia V. Sequist, Gerard A. Silvestri, Nichole Tanner, Jeffrey C. ThompsonAnil Vachani, Kwok-Kin Wong, Ali H. Zaidi, Joseph Catallini, Ariel Gershman, Keith LumbardLaurel K. MillbergJeff NawrockiCarter PortwoodAakanksha RangnekarCarolina Campos. Sheridan, Niti TrivediTony WuYuhua ZongLindsey CottonAllison RyanChristopher CisarAlessandro LealNicholas C. DracopoliRobert B. ScharpfVictor E. VelculescuLuke R. G. Pike.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023